ProMIS Neurosciences, Inc. (TSE:PMN – Get Free Report) shares dropped 3.8% on Monday . The company traded as low as C$5.98 and last traded at C$6.00. Approximately 19,701 shares changed hands during mid-day trading, an increase of 492% from the average daily volume of 3,327 shares. The stock had previously closed at C$6.24.
ProMIS Neurosciences Stock Performance
The company has a debt-to-equity ratio of 108.33, a quick ratio of 1.30 and a current ratio of 0.51. The company’s 50 day simple moving average is C$6.00. The firm has a market capitalization of C$51.48 million, a P/E ratio of -1.78 and a beta of 1.19.
ProMIS Neurosciences Company Profile
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Featured Stories
- Five stocks we like better than ProMIS Neurosciences
- Investing in the High PE Growth Stocks
- Why Block’s Key Components Make It a Solid Investment Choice
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Is Applied Digital’s Stock Set to Surge With NVIDIA’s Backing?
- 3 Warren Buffett Stocks to Buy Now
- 4 Reasons to Consider Adding General Mills to Your Portfolio
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
